Search Results

Fluocinonide 200 mg  | 100.00%

TargetMol

Fluocinonide (Vanos) is an effective glucocorticoid steroid, utilized in the treatment as the skin disorders anti-inflammatory agent.

More Information Supplier Page

BML-190 200 mg  | 99.51%

TargetMol

BML-190 (Indomethacin morpholinylamide) is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor.

More Information Supplier Page

AZD1981 25 mg  | 99.54%

TargetMol

AZD1981 is an effective and specific CRTh2 (DP2) receptor antagonist (IC50: 4 nM), showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. AZD1981 has been used in trials studying the treatment and basic science of Asthma, Postmenopausal, Pharmakokinetic, Asthma Patients, and Drug Interaction, among others.

More Information Supplier Page

(R)-(-)-Gossypol acetic acid 100 mg  | 96.73%

TargetMol

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID. Phase 2.

More Information Supplier Page

JK-P3 50 mg  | 99.50%

TargetMol

JK-P3 is a pyrazole-based inhibitor of VEGFR-2 (IC50: 7.8 μM). JK-P3 inhibits FGFR 1/3 kinase activity in vitro, but has no effect on FGFR signaling in cell-based assays. The compound blocks wound healing and tube formation in HUVEC without effecting endothelial cell proliferation.

More Information Supplier Page

JK-P3 10 mg  | 99.50%

TargetMol

JK-P3 is a pyrazole-based inhibitor of VEGFR-2 (IC50: 7.8 μM). JK-P3 inhibits FGFR 1/3 kinase activity in vitro, but has no effect on FGFR signaling in cell-based assays. The compound blocks wound healing and tube formation in HUVEC without effecting endothelial cell proliferation.

More Information Supplier Page

ML239 100 mg  | 99.54%

TargetMol

ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.

More Information Supplier Page

ML239 50 mg  | 99.54%

TargetMol

ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.

More Information Supplier Page

ML239 25 mg  | 99.54%

TargetMol

ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.

More Information Supplier Page